Founded in 2013, Frontier Biotechnologies Inc. ("Frontier Biotech") is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.
Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States.
Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, our long-standing commitment to excellence is in everything we do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.
Frontier Biotech was co-founded by three national distinguished experts, Dr. Dong Xie, Dr. Changjin Wang, and Dr. Rongjian Lu. Hailed as one of the leading biotechnology companies in China in the field of innovative drug development for HIV and AIDS treatments, Frontier Biotech has been the recipient of numerous awards and accolades over the years. Frontier Biotech has been named as the leading enterprise in the field of Anti-HIV Drug Development Special Project in the 13th "Five-Year Plan" New Drug Research and Development National Major Scientific and Technological Special Projects administered by State Ministry of Science and Technology. Frontier Biotech is also named as one of the "Cultivation of Unicorn Enterprises" in the city of Nanjing, China.
| Full name | FRONTIER BIOTECHNOLOGIES INC. |
|---|---|
| Abbreviations | Froniter Biotechnologies |
| Code | 688221 |
| Founded | 2013.01.15 |
| Listing | 2020.10.28 |
| Domicile | Nanjing, China |
| invest@frontierbiotech.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | -0.80 | -0.73 | -1.02 |
| R&D expenditure as a % of operating revenue | 297.05% | 409.50% | 5,203.29% |
| Operating Revenue | 46,62 | 20.86 | 1.91 |
| Net Income | -235.52 | -195.11 | -247.25 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 46,62 | 20.86 | 1.91 |
| Operating Costs | 38.04 | 31.26 | 11.99 |
| Operating Income | -235.44 | -193.49 | -247.73 |
| Pretax Income | -235.52 | -195.11 | -247.25 |
| Income Tax | - | - | - |
| Net Income | -235.52 | -195.11 | -247.25 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,848.17 | 456.11 | 389.30 |
| Non-current Assets-Total | 668.12 | 483.42 | 334.09 |
| Total Assets | 2,516.29 | 939.53 | 723.39 |
| Liabilities | |||
| Current Liabilities-Total | 112.71 | 82.44 | 29.27 |
| Non-current Liabilities-Total | 262.96 | 254.10 | 56.26 |
| Total Liabilities | 375.67 | 336.54 | 85.53 |
| Stockholder's Equity | |||
| Share Capital | 2,952.39 | 1,181.40 | 1,022.10 |
| Retained Profits | -809.35 | -578.57 | -386.06 |
| Minority Interests | -2.42 | 0.16 | 1.82 |
| Total Owners' Equity | 2,140.62 | 602.99 | 637.86 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | -170.17 | 34.29 | -79.13 |
| Net Cash Flows-Investing | -965.28 | -148.30 | 10.72 |
| Net Cash Flows-Financing | 1,747.63 | 153.61 | 233.96 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| BAOBAB PHARMACEUTICALSLIMITED | 70.64 | 19.63% |
| RONGJIAN LU | 21.74 | 6.04% |
| CHANGJIN WANG | 21.06 | 5.85% |
| 南京晟功企业管理合伙企业（有限合伙） | 19.83 | 5.51% |
| 重庆众诚鸿运商务信息咨询服务事务所（有限合伙） | 19.04 | 5.29% |
| 南京建木商务咨询合伙企业（有限合伙） | 17.20 | 4.78% |
| 北京鼎泽迅捷科技有限公司 | 14.30 | 3.97% |
| 南京建木生物技术有限公司 | 13.92 | 3.87% |
| 北京瑞丰投资管理有限公司 | 12.50 | 3.47% |
| 深圳市前海倚锋太和股权投资基金企业（有限合伙） | 9.77 | 2.72% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.